JP2022538084A5 - - Google Patents

Info

Publication number
JP2022538084A5
JP2022538084A5 JP2021576279A JP2021576279A JP2022538084A5 JP 2022538084 A5 JP2022538084 A5 JP 2022538084A5 JP 2021576279 A JP2021576279 A JP 2021576279A JP 2021576279 A JP2021576279 A JP 2021576279A JP 2022538084 A5 JP2022538084 A5 JP 2022538084A5
Authority
JP
Japan
Prior art keywords
approximately
gene
library
reagents
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038503 external-priority patent/WO2020257504A1/en
Publication of JP2022538084A publication Critical patent/JP2022538084A/ja
Publication of JP2022538084A5 publication Critical patent/JP2022538084A5/ja
Pending legal-status Critical Current

Links

JP2021576279A 2019-06-21 2020-06-18 ヒトの癌を対象とする包括的な機能プロファイリングのための遺伝子薬種 Pending JP2022538084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865047P 2019-06-21 2019-06-21
US62/865,047 2019-06-21
PCT/US2020/038503 WO2020257504A1 (en) 2019-06-21 2020-06-18 A genetic pharmacopeia for comprehensive functional profiling of human cancers

Publications (2)

Publication Number Publication Date
JP2022538084A JP2022538084A (ja) 2022-08-31
JP2022538084A5 true JP2022538084A5 (https=) 2023-06-27

Family

ID=74040921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576279A Pending JP2022538084A (ja) 2019-06-21 2020-06-18 ヒトの癌を対象とする包括的な機能プロファイリングのための遺伝子薬種

Country Status (8)

Country Link
US (1) US20220244244A1 (https=)
EP (1) EP3987087A4 (https=)
JP (1) JP2022538084A (https=)
KR (1) KR20220052902A (https=)
CN (1) CN114450440A (https=)
AU (1) AU2020294772A1 (https=)
CA (1) CA3144356A1 (https=)
WO (1) WO2020257504A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
JP2023541457A (ja) * 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ３８修飾のための化合物および方法
WO2022072643A1 (en) * 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
KR20240095529A (ko) * 2021-07-16 2024-06-25 오르토바이오 테라퓨틱스, 인크. 관절 기능 개선을 위한 유전자 편집
JP2024540723A (ja) * 2021-11-03 2024-11-01 インテリア セラピューティクス，インコーポレーテッド 免疫療法のためのｃｄ３８組成物及び方法
CN114703191A (zh) * 2022-04-19 2022-07-05 华南农业大学 基于crsipr技术构建rictor基因敲除细胞株的方法及其应用
AU2024217832A1 (en) * 2023-02-10 2025-10-02 Integrate Bioscience Llc Personalized crispr profiling for cancer
EP4698657A2 (en) * 2023-04-21 2026-02-25 Duke University Epigenetic targets for enhancing cancer immunotherapy
WO2025063185A1 (ja) * 2023-09-19 2025-03-27 国立大学法人東海国立大学機構 １本鎖ポリヌクレオチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
WO2015065964A1 (en) * 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof

Similar Documents

Publication Publication Date Title
JP2022538084A5 (https=)
Amero et al. Conversion of RNA aptamer into modified DNA aptamers provides for prolonged stability and enhanced antitumor activity
Mathews et al. Adenovirus virus-associated RNA and translation control
Ivashchenko et al. How miRNAs can protect humans from coronaviruses COVID-19, SARS-CoV, and MERS-CoV
Gao et al. BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle‐invasive bladder cancers: A microarray pathway analysis
KR20200044695A (ko) Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물
CN114042160B (zh) Ctd-2256p15.2及其编码微肽作为靶点在开发肿瘤治疗药物中的应用
Lv et al. Cofilin acts as a booster for progression of malignant tumors represented by glioma
CN109022461A (zh) 一种PTEN基因的上游开放阅读框45aa-uORF核苷酸序列及其编码的多肽的应用
Yuan et al. Newcastle disease virus activates methylation-related enzymes to reprogram m6A methylation in infected cells
CN112522267A (zh) 长链非编码rna在调控结直肠癌5-fu耐药的应用
JP6286050B2 (ja) トリインフルエンザウイルスのｍｉＲＮＡとその同定、検出および使用
CN119380801B (zh) 一种基于trim56和sting的计算机辅助药物筛选方法、系统及设备
Ren et al. Comparative transcriptome analysis of long non coding RNA (lncRNA) in RTG-2 cells infected by infectious hematopoietic necrosis virus
Yun et al. Single-cell transcriptional profiling reveals cell type-specific responses to duck reovirus infection in the Bursa of Fabricius of Cairna moschata
CN104711240B (zh) 禽呼肠孤病毒σA蛋白及其相关生物材料的应用
CN109562121A (zh) 转移性癌症的诊断和治疗方法
CN105907757A (zh) Linc00052基因的用途及其相关药物
JP2024529939A5 (https=)
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
Xu et al. Integrated transcriptomic and metabolomic analysis identifies host response mechanisms to oncogenic Marek’s disease virus in Wenchang chickens
Wang et al. The σNS protein of NDRV antagonizes TRIM59-mediated antiviral innate immune response of Cherry Valley duck
Uhlmann et al. Influence of osteopontin expression on the metastatic growth of CC531 rat colorectal carcinoma cells in rat liver
Hoque et al. Design of potential siRNA molecules for T antigen gene silencing of Merkel Cell Polyomavirus
CN119386186A (zh) Tfe3在调控slco4a1及在治疗癌症中的应用